Skip to content
Screener

10x Genomics, Inc. TXG Single Cell — Revenue

Other product segments

Products and services revenue
$149.09M+2.7%
Services
$10.68M+26.0%
Spatial
$4.57M-47.8%
License and royalty revenue
$1.94M-93.0%

Similar metrics at other companies

Pure Cycle logo
PCYOSingle Family Rentals — Revenue
$231K+76.3%
Beta Bionics logo
BBNXSingle Use Products — Revenue
$11.38M+118%
Expro Group Holdings logo
XPROWell Construction — Revenue
$122.61M-6.0%
Fluent, Inc. logo
FLNTCall Solutions — Revenue
$1.21M-88.0%
Expro Group Holdings logo
XPROWell Management — Revenue
$244.97M-5.9%
Textron logo
TXTBell — Revenue
$1.07B+5.7%

Other financials

Income statement

See full
Revenue$151.0M-12.6%
Gross profit$112.5M-10.1%
Operating income-$19.6M-165%
Net income-$17.9M-152%
EPS (diluted)-$0.14-150%

Balance sheet

See full
Cash & equivalents$502.5M+26.4%
Total debt$78.8M-9.2%
Total equity$825.5M+6.8%
Total assets$1.0B+5.1%

Cash flow

See full
Operating cash flow$17.0M-4.1%
CapEx$1.6M+0.6%
Free cash flow$15.4M-4.6%

Valuation

See full
Market cap$5.79B+271%
Enterprise value$5.37B+330%
P/S9.4×+7.0×

Profitability

See full
Gross margin70%+0.5pp
Operating margin-14.3%-1.1pp
Net margin-12.2%-0.8pp
FCF margin19.7%+10.9pp

Returns & leverage

See full
Return on equity-9.4%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.7×-0.1×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054491
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Instruments
Single Cell$3,087$5,727$8,310$11,640
Spatial4,5748,77010,61317,672
Total instruments revenue7,66114,49718,92329,312
Consumables
Single Cell88,45185,788177,345169,897
Spatial42,30136,39783,20867,644
Total consumables revenue130,752122,185260,553237,541

Item 1. Financial Statements (Unaudited)

FAQ

What is 10x Genomics, Inc.'s single cell — revenue?
10x Genomics, Inc. (TXG) reported single cell — revenue of $3.09M in Q2 2026.
How has 10x Genomics, Inc.'s single cell — revenue changed year-over-year?
10x Genomics, Inc.'s single cell — revenue decreased by 46.1% year-over-year, from $5.73M to $3.09M.
What is the long-term trend for 10x Genomics, Inc.'s single cell — revenue?
Over 3 years (2021 to 2024), 10x Genomics, Inc.'s single cell — revenue has grown at a -18.1% compound annual growth rate (CAGR), from $64.17M to $35.21M.
What does single cell — revenue mean?
This metric represents the total revenue generated specifically from the sale of instruments within the single-cell analysis product line. It serves as a key indicator of market adoption for the company's core hardware platforms used in biological research. Tracking this revenue stream helps investors assess the installed base growth and the potential for recurring demand for associated consumables.

Ask your AI about 10x Genomics, Inc.'s single cell — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude